"Dr Garner says his focus has been to evolve the company away from its traditional model........"
".....he says Novogen has tried to think about its business in a different way, looking to "win" one part of the process, such as late stage clinical development to phase 2...."
"We want to identify drugs in large pharmaceutical companies where some investment has already been made. We can take it into the next stage and then partner to commercialise. I suppose we're really looking to own drugs for 3 to 6 years. The opportunity exists because large companies tend to produce more intellectual property than they can actually commercialise"
"Dr Garner says Novogen's interest in GDC-0084 did result in Genentech taking another look at the molecule. He says it is even possible the company, which is wholly owned by Roche, could license it back in the future."
NRT Price at posting:
4.2¢ Sentiment: Buy Disclosure: Held
